What Envigo does

Envigo is a research models and preclinical services business now operating as part of Inotiv, Inc. (NASDAQ: NOTV). Originally founded as a standalone entity headquartered in Huntingdon, United Kingdom, Envigo was acquired by Inotiv in July 2022 and integrated into the parent company's Research Models and Services segment. The combined business provides a broad portfolio of laboratory research models (rat, mouse, and genetically engineered models), supporting services (contract breeding, surgical services, genetic testing, biospecimen services), and Teklad-branded laboratory animal diets, bedding, and enrichment products to pharmaceutical, biotechnology, government, and academic clients worldwide.

The underlying technology stack centers on proprietary animal model production, comprehensive health monitoring programs, custom genetically engineered model (GEMS) services, and supporting software including Eusoft Labs LIMS and LabTracks for research model tracking. Within the broader Inotiv portfolio, Envigo's capabilities complement nonclinical CRO services spanning 10 therapeutic areas (cardiovascular, GI, hepatic, infectious disease, inflammation and immunology, metabolic disease, neuroscience, oncology, pulmonary, renal) and three research phases (discovery, IND-enabling, pre-marketing authorization). Adjacent technical capabilities include digital pathology with AI-driven quantitative image analysis and proprietary mass spectrometry assays for 27 antibody-drug conjugate targets.

Envigo's revenue model combines one-time unit sales of research models and Teklad products with multi-year contract research service agreements. Research models are priced on a per-unit basis depending on model type, genetics, and health status, with a 2025-2026 Product Guide publicly available. CRO services are quoted on a study-by-study basis with multi-year contracts. Customers include large pharmaceutical and biotechnology companies (primary segment), government agencies, and academic institutions. The business reaches customers through enterprise field sales, scientific content marketing, industry conference participation, and direct e-commerce for Teklad products.

Name

Envigo

Legal name

Inotiv, Inc.

Website

https://envigo.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Envigo provides laboratory research models, genetically engineered models, and supporting preclinical services and products (Teklad diets, bedding) to pharmaceutical, biotech, government, and academic clients worldwide. Now part of Inotiv, Inc. (NASDAQ: NOTV) following 2022 acquisition.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

In Vivo Pharmacology (Efficacy/PD Models) (HLAGAFAA)

akta.pro secondary industry

DMPK / ADME & Bioanalysis (HLAGAFAC)

Keywords

• Research models supply
• Preclinical contract research
• Laboratory animal diets
• Drug discovery services
• Toxicology testing services

Headquarters

HQ city

Huntingdon

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Discovery and Development Services: Fee-for-service contract research organization providing nonclinical and analytical services including discovery sciences, safety assessment, and bioanalysis. Services are provided across multiple therapeutic areas and research phases for pharmaceutical and biotech clients.
2. Research Models and Services: Sale of research models (including rat, mouse, and other animal models) and related services such as contract breeding, surgical services, genetic testing, and biospecimen services to pharmaceutical, biotech, government, and academic clients.
3. Teklad Diet and Bedding Products: Laboratory animal diets, bedding, and enrichment products sold to research institutions and pharmaceutical companies to support animal research programs.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Envigo supplies research models (rats, mice, and other species), Teklad laboratory animal diets, bedding and enrichment products, and related services to pharmaceutical, biotechnology, government, and academic research customers. As part of Inotiv, it also delivers nonclinical contract research services spanning disease pharmacology, DMPK, toxicology, histology/pathology, and genetically engineered model services across ten therapeutic areas.

Product overview

Based on the provided source data, there is no information about Envigo's products or services. The source material references Inotiv, Inc. (a Discovery and Development CRO at inotiv.com), but does not contain any information about Envigo specifically.

Differentiator

Problem solved

Functional benefit

Products and services

• Discovery and Translational Sciences Nonclinical contract research services covering disease pharmacology (in vitro and in vivo), drug metabolism and pharmacokinetics (DMPK), discovery bioanalysis and biomarkers, cell and molecular biology, predictive and computational toxicology, toxicogenomics, targeted proteomics, histology and pathology, and consultative drug discovery programs, for pharmaceutical and biotech customers.
• Safety Assessment Services GLP and non-GLP toxicology, safety pharmacology, genetic toxicology, developmental and reproductive toxicology (DART), carcinogenicity, pathology, GLP bioanalysis for small and large molecules, impurities assessment, SEND, cell and gene therapy safety, medical device testing, and program management for pharmaceutical and biotech customers.
• Research Models Sale of rat, mouse, and other animal research models to pharmaceutical, biotechnology, government, and academic customers, with options for standard models, genetically engineered models, and specialized disease models.
• Research Model Services Genetically Engineered Models and Services (GEMS), Full Spectrum Health Monitoring, Custom Antibody Production Services, Biospecimen Services, Contract Breeding Services, Genetic Testing Services, Surgical Services, and Research Model Support Services for pharmaceutical, biotech, government, and academic customers.
• Teklad Laboratory Animal Diets Standard natural ingredient diets, custom research diets, and medicated laboratory animal diets designed to support consistent and reliable research data for research institutions and pharmaceutical companies.
• Teklad Bedding and Environmental Enrichment Products Contact bedding, custom-cut paper cage liners, and welfareplus enrichment products sold to research institutions and pharmaceutical companies to support animal research programs.

Quantifiable outcome

• ADC assays developed for 27 targets supporting oncology and other therapeutic applications
• +1 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Three partnerships are on record, tiered core and minor.

• PharmaLegacycoreStrategic or Co-development Partner · 1 October 2024Catawba Research partnership with PharmaLegacy announced in October 2024. This represents a strategic collaboration in the preclinical CRO space, strengthening capabilities for global biopharmaceutical clients. PharmaLegacy had previously acquired BTS Research (US-based preclinical CRO) in September 2024 to expand laboratory footprint in North America.
• BTS Research Inc.minorOthersBTS Research Inc., a United States-based preclinical CRO, was acquired by China-based PharmaLegacy Laboratories Co. Ltd. in September 2024. This acquisition expanded PharmaLegacy's laboratory footprint in North America to strengthen support for global biopharmaceutical clients.
• Catawba ResearchcoreStrategic or Co-development PartnerCatawba Research partnered with PharmaLegacy in October 2024, representing a strategic collaboration in the preclinical CRO market.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Medpace Holdings: Medpace is a mid-to-large CRO with growing preclinical and clinical pharmacology capabilities. Targets similar small-to-mid biotech customer segment where the subject company is exposed, though Medpace is more clinical-phase oriented.
• IQVIA: IQVIA is the largest clinical CRO with growing preclinical and laboratory services capabilities. Competes for pharma R&D outsourcing budgets and increasingly for early development work where Inotiv/Envigo is positioned.
• ICON plc (PRA Health merger): ICON is a major CRO with preclinical and clinical capabilities, serving overlapping pharma/biotech customers. While ICON is more clinical-focused post-PRA merger, its early-phase and bioanalytical labs compete for the same preclinical budgets.
• Eurofins Scientific: Eurofins is a broad life sciences testing services conglomerate with preclinical and bioanalytical capabilities. Overlaps with the company in safety assessment, bioanalysis, and pharmaceutical testing, though Eurofins is far larger and more diversified.
• Thermo Fisher Scientific (PPD): Thermo Fisher's PPD division provides preclinical through clinical CRO services globally. As a top-tier incumbent with deep pharma relationships, PPD competes for early development studies and bioanalytical work historically served by mid-tier CROs.
• Labcorp (incl. Fortrea spin-off): Labcorp's early development CRO business (now Fortrea) provides nonclinical safety, DMPK, and bioanalytical services with global lab footprint. Fortrea is a direct competitor to Inotiv's discovery and safety assessment offerings across similar pharma/biotech customers.
• Charles River Laboratories: Charles River is the largest direct competitor in preclinical CRO and research models, offering RMS, safety assessment, and discovery services across all major therapeutic areas. Overlaps directly with the company's Envigo research models and Inotiv CRO services, but at substantially larger scale.

Direct peers

• Wuxi AppTec: Wuxi AppTec is a leading global preclinical and discovery CRO with extensive DMPK, toxicology, and biology services. Direct competitor in IND-enabling preclinical work and serves many of the same US/EU pharma clients as the subject company.
• Pharmaron: Pharmaron provides integrated drug discovery, DMPK, safety assessment, and biologics services with a strong China-UK-US footprint. Directly comparable service portfolio to Inotiv/Envigo with similar mid-tier CRO positioning.

Emerging players

• Samsung Biologics / Curogene (Crogenic): Samsung Biologics and adjacent Korean/Asian preclinical CROs are emerging players expanding into Western pharma preclinical services. They represent new competitive entrants particularly in cell/gene therapy and biologics safety assessment adjacent to the subject company's capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/envigo-
• Xx.com/WeAreENVIGO

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Envigo